Crohn’s-Like Lymphoid Reaction is Associated with Oncological Prognosis and Nutritional Status in Patients with Pathological Stage II/III Gastric Cancer
- 34 Downloads
Peritumoral lymphoid aggregates, termed Crohn’s-like lymphoid reaction (CLR), are markers of an antitumor immune response, which is an important predictor of patient outcome. In this study, we investigated the prognostic utility of CLR and its relationship with nutritional status in patients with gastric cancer (GC).
The study included 170 patients who underwent curative surgery for pathological stage (pStage) II/III GC. The maximum diameters of peritumoral and normal mucosal CLR aggregates were measured, and the median peritumoral diameter (0.57 mm) was used to stratify patients into two groups (large-CLR and small-CLR). The relationships between CLR size and preoperative nutritional status (body mass index, body composition status, Onodera’s prognostic nutritional index), tumor-infiltrating CD8+ T-lymphocyte count, and survival were evaluated.
Peritumoral CLR aggregates were significantly larger than aggregates in the normal mucosa. Clinicopathological variables were not significantly different between the two patient groups; however, the large-CLR group had better cancer-specific survival (p = 0.018) and recurrence-free survival (p = 0.03) than the small-CLR group. Multivariate analysis revealed that CLR size was an independent prognostic factor for cancer-specific survival [hazard ratio (HR) 2.13, 95% confidence interval (CI) 1.3–3.56, p = 0.002] and recurrence-free survival (HR 1.96, 95% CI 1.22–3.19, p = 0.005). Nutritional status markers were significantly poorer for the small-CLR group than the large-CLR group. CD8+ T-cell tumor infiltration was positively correlated with CLR size but not with patient survival.
CLR size correlated with patient nutritional status and prognosis and may be helpful in identifying high-risk populations of pStage II/III GC patients.
The authors thank Yuki Orito and Amphone Okada for excellent technical assistance, and Anne M. O’Rourke, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Study conception and design: YuO, YT, YoO, and MK. Acquisition and analysis of the data: YuO, YT, YoO, AY, CY, KK, YK, TS, SI, TK, HF, HY, JH, SY, and MO. Interpretation of the data: YuO, YT, and YoO. Drafting of the manuscript: YuO, YT, YoO, and MK. Critical revision of the manuscript: YuO, YT, YoO, AY, CY, KK, YK, TS, SI, TK, HF, HY, JH, SY, MO, and MK.
Part of this study was supported by a Grant-in-Aid for Scientific Research (16K10533) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
Yusuke Omura, Yuji Toiyama, Yoshinaga Okugawa, Akira Yamamoto, Chengzeng Yin, Kurando Kusunoki, Yukina Kusunoki, Tsunehiko Shigemori, Shozo Ide, Takahito Kitajima, Hiroyuki Fujikawa, Hiromi Yasuda, Junichiro Hiro, Shigeyuki Yoshiyama, Masaki Ohi, and Masato Kusunoki have no conflicts of interest to disclose.
- 4.Suzuki Y, Oshima T, Yoshihara K, et al. Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1. Oncol Lett. 2018;15(5):7335–43.Google Scholar
- 5.Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.CrossRefGoogle Scholar
- 8.Graham DM, Appelman HD. Crohn’s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1990;3(3):332–5.Google Scholar
- 21.Wang HX, Wang CC, Yang W, Gao LL, Yu SQ. Prognostic value of preoperative prognostic nutritional index in stage III gastric cancer after curative resection: a retrospective cohort study. Asia Pac J Clin Nutr. 2018;27(3):540–5.Google Scholar
- 25.Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients [in Japanese]. Nihon Geka Gakkai zasshi. 1984;85(9):1001–5.Google Scholar